The molecular mechanisms of action of bisphosphonates

Clinical Reviews in Bone and Mineral Metabolism

Volumn 5, Issue 3, 2007, Pages 130-144

  Thompson, Keith ^a   Rogers, Michael J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

T cell; Bisphosphonate; Bone resorption; Farnesyl diphosphate; GTPase; Mevalonate; Osteoclast; Prenylation

Indexed keywords

ADENOSINE TRIPHOSPHATE DERIVATIVE; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; COMPACTIN; DEXAMETHASONE; DRUG METABOLITE; ETIDRONIC ACID; ETOPOSIDE; GERANYLTRANSFERASE; GUANOSINE TRIPHOSPHATASE; IBANDRONIC ACID; INTERLEUKIN 2; ISOPRENOID; MEVINOLIN; MINODRONIC ACID; NE 10571; NE 11808; NE 11809; NE 21650; NITROGEN; OLPADRONIC ACID; PAMIDRONIC ACID; PREDNISOLONE; RISEDRONIC ACID; TILUDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE METASTASIS; BONE MINERALIZATION; CELL DEATH; DIARRHEA; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ESOPHAGITIS; FLU LIKE SYNDROME; HUMAN; LYMPHOMA; NAUSEA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PAIN; PRENYLATION; REVIEW; SIGNAL TRANSDUCTION; STOMACH ULCER; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 49349111042     PISSN: 15348644     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12018-007-9004-0     Document Type: Review

References (133)

1. PD Delmas 2005 The use of bisphosphonates in the treatment of osteoporosis Curr Opin Rheumatol 17 462 6
2. AL Langston SH Ralston 2004 Management of Paget's disease of bone Rheumatology (Oxford) 43 955 9
3. P Conte R Coleman 2004 Bisphosphonates in the treatment of skeletal metastases Semin Oncol 31 59 63
4. RGG Russell S Bisaz H Fleisch HL Currey HM Rubinstein AA Dietz I Boussina A Micheli G Fallet 1970 Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout) Lancet 2 899 902
5. A Jung S Bisaz H Fleisch 1973 The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals Calcif Tissue Res 11 269 80
6. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2005;38:617-27.
7. CT Leu E Luegmayr LP Freedman GA Rodan AA Reszka 2006 Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy Bone 38 628 36
8. JH Lin 1996 Bisphosphonates: a review of their pharmacokinetic properties Bone 18 75 85
9. M Sato W Grasser N Endo R Akins H Simmons DD Thompson E Golub GA Rodan 1991 Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure J Clin Invest 88 2095 105
10. P Masarachia M Weinreb R Balena GA Rodan 1996 Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones Bone 19 281 90
11. FH Ebetino MD Francis MJ Rogers RGG Russell 1998 Mechanisms of action of etidronate and other bisphosphonates Rev Contemp Pharmacother 9 233 43
12. Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonates into macrophages and osteoclasts requires fluid-phase endocytosis and endosomal acidification. Mol Pharmacol 2006;69:1624-32.
13. RGG Russell RC Muhlbauer S Bisaz DA Williams H Fleisch 1970 The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats Calcif Tissue Res 6 183 96
14. HL Benford JC Frith S Auriola J Monkkonen MJ Rogers 1999 Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs Mol Pharmacol 56 131 40
15. EJ Rowe E Hausmann 1976 The alteration of osteoclast morphology by diphosphonates in bone organ culture Calcif Tissue Res 20 53 60
16. R Schenk WA Merz R Muhlbauer RGG Russell H Fleisch 1973 Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats Calcif Tissue Res 11 196 214
17. DE Hughes KR Wright HL Uy A Sasaki T Yoneda GD Roodman GR Mundy BF Boyce 1995 Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo J Bone Miner Res 10 1478 87
18. MJ Rogers KM Chilton FP Coxon J Lawry MO Smith S Suri RGG Russell 1996 Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism J Bone Miner Res 11 1482 91
19. KS Selander J Monkkonen EK Karhukorpi P Harkonen R Hannuniemi HK Vaananen 1996 Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages Mol Pharmacol 50 1127 38
20. MJ Rogers 2004 From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates Calcif Tissue Int 75 451 61
21. MJ Rogers RJ Brown V Hodkin GM Blackburn RGG Russell DJ Watts 1996 Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes Biochem Biophys Res Commun 224 863 9
22. JC Frith J Monkkonen GM Blackburn RG Russell MJ Rogers 1997 Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma- dichloromethylene) triphosphate, by mammalian cells in vitro J Bone Miner Res 12 1358 67
23. S Auriola J Frith MJ Rogers A Koivuniemi J Monkkonen 1997 Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry J Chromatogr B 704 187 95
24. JC Frith J Monkkonen S Auriola H Monkkonen MJ Rogers 2001 The molecular mechanism of action of the anti-resorptive and anti-inflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis Arthritis and Rheum 44 2201 10
25. MJ Rogers X Ji RG Russell GM Blackburn MP Williamson AV Bayless FH Ebetino DJ Watts 1994 Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum Biochem J 303 303 11
26. H Monkkonen MJ Rogers N Makkonen S Niva S Auriola J Monkkonen 2001 The cellular uptake and metabolism of clodronate in RAW 264 macrophages Pharm Res 18 1550 5
27. PP Lehenkari M Kellinsalmi JP Napankangas KV Ylitalo J Monkkonen MJ Rogers A Azhayev HK Vaananen IE Hassinen 2002 Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite Mol Pharmacol 61 1255 62
28. HL Benford NW McGowan MH Helfrich ME Nuttall MJ Rogers 2001 Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro Bone 28 465 73
29. AA Reszka JM Halasy-Nagy PJ Masarachia GA Rodan 1999 Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase J Biol Chem 274 34967 73
30. MJ Rogers 2003 New insights into the molecular mechanisms of action of bisphosphonates Curr Pharm Des 9 2643 58
31. JR Green MJ Rogers 2002 Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption Drug Dev Res 55 210 24
32. E van Beek E Pieterman L Cohen C Lowik S Papapoulos 1999 Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates Biochem Biophys Res Commun 264 108 11
33. JD Bergstrom RG Bostedor PJ Masarachia AA Reszka G Rodan 2000 Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase Arch Biochem Biophys 373 231 41
34. JE Dunford K Thompson FP Coxon SP Luckman FM Hahn CD Poulter FH Ebetino MJ Rogers 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates J Pharmacol Exp Ther 296 235 42
35. JM Rondeau F Bitsch M Geiser R Hemmig M Kroemer S Lehmann P Ramage S Rieffel A Strauss JR Green W Jahnke 2006 Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs Chem Med Chem 1 267 73
36. K Kavanagh K Guo JE Dunford X Wu S Knapp FH Ebetino MJ Rogers RGG Russell U Oppermann 2006 The molecular mechanism of nitrogen-containing bisphosphonates as anti-osteoporosis drugs: crystal structure and inhibition of farnesyl pyrophosphate synthase Proc Natl Acad Sci USA 103 7829 34
37. MB Martin W Arnold HT Heath JA Urbina E Oldfield 1999 Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis Biochem Biophys Res Commun 263 754 8
38. DJ Hosfield Y Zhang DR Dougan A Brooun LW Tari RV Swanson J Finn 2003 Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis J Biol Chem 279 8526 9
39. FH Ebetino CN Roze CE McKenna BL Barnett JE Dunford RGG Russell GE Mieling MJ Rogers 2005 Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase J Organomet Chem 690 2679 87
40. JL Goldstein MS Brown 1990 Regulation of the mevalonate pathway Nature 343 425 30
41. FL Zhang PJ Casey 1996 Protein prenylation: molecular mechanisms and functional consequences Ann Rev Biochem 65 241 69
42. M Sinensky 2000 Recent advances in the study of prenylated proteins Biochim Biophys Acta 1484 93 106
43. FP Coxon FH Ebetino EH Mules MC Seabra CE McKenna MJ Rogers 2005 Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo Bone 37 349 58
44. SP Luckman DE Hughes FP Coxon RGG Russell MJ Rogers 1998 Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras J Bone Miner Res 13 581 9
45. M Sato W Grasser 1990 Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy J Bone Miner Res 5 31 40
46. V Breuil F Cosman L Stein W Horbert J Nieves V Shen R Lindsay DW Dempster 1998 Human osteoclast formation and activity in vitro: effects of alendronate J Bone Miner Res 13 1721 9
47. FP Coxon MH Helfrich RJ van't Hof SM Sebti SH Ralston AD Hamilton MJ Rogers 2000 Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298 J Bone Miner Res 15 1467 76
48. A Staal JC Frith MH French J Swartz T Gungor TW Harrity J Tamasi MJ Rogers JH Feyen 2003 The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity J Bone Miner Res 18 88 96
49. JE Fisher GA Rodan AA Reszka 2000 In vivo effects of bisphosphonates on the osteoclast mevalonate pathway Endocrinology 141 4793 6
50. AA Reszka J Halasy-Nagy GA Rodan 2001 Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation Mol Pharmacol 59 193 202
51. FP Coxon MJ Rogers 2003 The role of prenylated small GTP-binding proteins in the regulation of osteoclast function Calcif Tissue Int 72 80 4
52. E Hiroi-Furuya T Kameda K Hiura H Mano K Miyazawa Y Nakamaru M Watanabe-Mano N Okuda J Shimada Y Yamamoto Y Hakeda M Kumegawa 1999 Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts Calcif Tissue Int 64 219 23
53. H Murakami N Takahashi T Sasaki N Udagawa S Tanaka I Nakamura D Zhang A Barbier T Suda 1995 A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders Bone 17 137 44
54. K Selander P Lehenkari HK Vaananen 1994 The effects of bisphosphonates on the resorption cycle of isolated osteoclasts Calcif Tissue Int 55 368 75
55. FP Coxon MH Helfrich B Larijani M Muzylak JE Dunford D Marshall AD McKinnon SA Nesbitt MA Horton MC Seabra FH Ebetino MJ Rogers 2001 Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages J Biol Chem 276 48213 22
56. UH Lerner A Larsson 1987 Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro Bone 8 179 89
57. Z Zimolo G Wesolowski GA Rodan 1995 Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin J Clin Invest 96 2277 83
58. H Zhao T Laitala-Leinonen V Parikka HK Vaananen 2001 Downregulation of small GTPase rab7 impairs osteoclast polarization and bone resorption J Biol Chem 276 39295 302
59. NJ Pavlos J Xu D Riedel JS Yeoh SL Teitelbaum JM Papadimitriou R Jahn FP Ross MH Zheng 2005 Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption Mol Cell Biol 25 5253 69
60. A Alakangas K Selander M Mulari J Halleen P Lehenkari J Monkkonen J Salo K Vaananen 2002 Alendronate disturbs vesicular trafficking in osteoclasts Calcif Tissue Int 70 40 7
61. JM Halasy-Nagy GA Rodan AA Reszka 2001 Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis Bone 29 553 9
62. Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42 and Rho GTPases. J Bone Miner Res 2006;21:684-94.
63. JE Fisher MJ Rogers JM Halasy SP Luckman DE Hughes PJ Masarachia G Wesolowski RGG Russell GA Rodan AA Reszka 1999 Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro Proc Natl Acad Sci USA 96 133 8
64. E van Beek C Lowik G Van der Pluijm S Papapoulos 1999 The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates J Bone Miner Res 14 722 9
65. ER van Beek LH Cohen IM Leroy FH Ebetino CW Lowik SE Papapoulos 2003 Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates Bone 33 805 11
66. G Mundy R Garrett S Harris J Chan D Chen G Rossini B Boyce M Zhao G Gutierrez 1999 Stimulation of bone formation in vitro and in rodents by statins Science 286 1946 9
67. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HA. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004;164:146-52.
68. P David H Nguyen A Barbier R Baron 1996 The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase J Bone Miner Res 11 1498 507
69. A Carano SL Teitelbaum JD Konsek PH Schlesinger HC Blair 1990 Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro J Clin Invest 85 456 61
70. O Teronen P Heikkila YT Konttinen M Laitinen T Salo R Hanemaaijer A Teronen P Maisi T Sorsa 1999 MMP inhibition and downregulation by bisphosphonates Ann N Y Acad Sci 878 453 65
71. R Felix R Graham G Russell H Fleisch 1976 The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes Biochim Biophys Acta 429 429 38
72. K Skorey HD Ly J Kelly M Hammond C Ramachandran Z Huang MJ Gresser Q Wang 1997 How does alendronate inhibit protein-tyrosine phosphatases? J Biol Chem 272 22472 80
73. A Schmidt SJ Rutledge N Endo EE Opas H Tanaka G Wesolowski CT Leu Z Huang C Ramachandaran SB Rodan GA Rodan 1996 Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate Proc Natl Acad Sci USA 93 3068 73
74. H Murakami N Takahashi S Tanaka I Nakamura N Udagawa S Nakajo K Nakaya M Abe Y Yuda F Konno A Barbier T Suda 1997 Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts Bone 20 399 404
75. PM Boonekamp LJA van der Wee-Pals MLL van Wijk-van Lennep CW Thesing OLM Bijvoet 1986 Two modes of action of bisphosphonates on osteoclastic resorption of mineralised matrix Bone Miner 1 27 39
76. DE Hughes BR McDonald RGG Russell M Gowen 1989 Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow J Clin Invest 83 1930 5
77. AM Flanagan TJ Chambers 1991 Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone Calcif Tissue Int 49 407 15
78. JM Owens K Fuller TJ Chambers 1997 Osteoclast activation: potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism J Cell Physiol 172 79 86
79. DK Fast R Felix C Dowse WF Neuman H Fleisch 1978 The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture Biochem J 172 97 107
80. N Endo SJ Rutledge EE Opas R Vogel GA Rodan A Schmidt 1996 Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates J Bone Miner Res 11 535 43
81. S Varghese E Canalis 2000 Alendronate stimulates collagenase 3 expression in osteoblasts by posttranscriptional mechanisms J Bone Miner Res 15 2345 51
82. GG Reinholz B Getz L Pederson ES Sanders M Subramaniam JN Ingle TC Spelsberg 2000 Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts Cancer Res 60 6001 7
83. M Sahni HL Guenther H Fleisch P Collin TJ Martin 1993 Bisphosphonates act on rat bone resorption through mediation of osteoblasts J Clin Invest 91 2004 10
84. X Yu J Scholler NT Foged 1996 Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106 Bone 19 339 45
85. M Nishikawa T Akatsu Y Katayama Y Yasutomo S Kado N Kugal M Yamamoto N Nagata 1996 Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures Bone 18 9 14
86. C Vitte H Fleisch HL Guenther 1996 Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption Endocrinology 137 2324 33
87. LI Plotkin RS Weinstein AM Parfitt PK Roberson SC Manolagas T Bellido 1999 Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin J Clin Invest 104 1363 74
88. I Mathov LI Plotkin CL Sgarlata J Leoni T Bellido 2001 Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro J Bone Miner Res 16 2050 6
89. LI Plotkin SC Manolagas T Bellido 2002 Transduction of cell survival signals by connexin-43 hemichannels J Biol Chem 277 8648 57
90. P Clezardin FH Ebetino PG Fournier 2005 Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity Cancer Res 65 4971 4
91. JR Green 2004 Bisphosphonates: preclinical review Oncologist 9 Suppl 4 3 13
92. CM Shipman PI Croucher RGG Russell MH Helfrich MJ Rogers 1998 The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway Cancer Res 58 5294 7
93. SS Virtanen HK Vaananen PL Harkonen PT Lakkakorpi 2002 Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway Cancer Res 62 2708 14
94. JP Coxon GM Oades RS Kirby KW Colston 2004 Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation BJU Int 94 164 70
95. K Sawada K Morishige M Tahara R Kawagishi Y Ikebuchi K Tasaka Y Murata 2002 Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho Cancer Res 62 6015 20
96. S Boissier S Magnetto L Frappart B Cuzin FH Ebetino PD Delmas P Clezardin 1997 Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices Cancer Res 57 3890 4
97. S Boissier M Ferreras O Peyruchaud S Magnetto FH Ebetino M Colombel P Delmas JM Delaisse P Clezardin 2000 Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases Cancer Res 60 2949 54
98. M Bezzi M Hasmim G Bieler O Dormond C Ruegg 2003 Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt J Biol Chem 278 43603 14
99. S Yamagishi R Abe Y Inagaki K Nakamura H Sugawara D Inokuma H Nakamura T Shimizu M Takeuchi A Yoshimura R Bucala H Shimizu T Imaizumi 2004 Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling Am J Pathol 165 1865 74
100. T Hiraga PJ Williams A Ueda D Tamura T Yoneda 2004 Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model Clin Cancer Res 10 4559 67
101. E Giraudo M Inoue D Hanahan 2004 An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis J Clin Invest 114 623 33
102. S Matsumoto S Kimura H Segawa J Kuroda T Yuasa K Sato M Nogawa F Tanaka T Maekawa H Wada 2005 Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines Lung Cancer 47 31 9
103. K Hashimoto K Morishige K Sawada M Tahara R Kawagishi Y Ikebuchi M Sakata K Tasaka Y Murata 2005 Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model Cancer Res 65 540 5
104. van der Pluijm G, Que I, Sijmons B, Buijs JT, Lowik CW, Wetterwald A, Thalmann GN, Papapoulos SE, Cecchini MG. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res 2005;65:7682-90.
105. Fitton A, McTavish D. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease [published erratum appears in Drugs 1992 Feb;43(2):145]. Drugs 1991;41:289-318.
106. G Maconi GB Porro 1995 Multiple ulcerative esophagitis caused by alendronate Am J Gastroenterol 90 1889 90
107. DY Graham 1998 Excess gastric ulcers are associated with alendronate therapy Am J Gastroenterol 93 1395 6
108. PC de Groen DF Lubbe LJ Hirsch A Daifotis W Stephenson D Freedholm S Pryor-Tillotson MJ Seleznick H Pinkas KK Wang 1996 Esophagitis associated with the use of alendronate N Engl J Med 335 1016 21
109. EG Lufkin R Argueta MD Whitaker AL Cameron VH Wong KS Egan WM O'Fallon BL Riggs 1994 Pamidronate: an unrecognized problem in gastrointestinal tolerability Osteoporos Int 4 320 2
110. DY Graham HM Malaty 1999 Alendronate gastric ulcers Aliment Pharmacol Ther 13 515 9
111. T van Staa L Abenhaim C Cooper 1997 Upper gastrointestinal adverse events and cyclical etidronate Am J Med 103 462 7
112. GL Plosker KL Goa 1994 Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease Drugs 47 945 82
113. S Suri J Monkkonen M Taskinen J Pesonen MA Blank RJ Phipps MJ Rogers 2001 Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity Bone 29 336 43
114. FL Lanza RH Hunt AB Thomson JM Provenza MA Blank 2000 Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women Gastroenterology 119 631 8
115. LM Lichtenberger JJ Romero GW Gibson MA Blank 2000 Effect of bisphosphonates on the surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa Dig Dis Sci 45 1792 801
116. S Adami AK Bhalla R Dorizzi F Montesanti S Rosini G Salvagno V Lo Cascio 1987 The acute-phase response after bisphosphonate administration Calcif Tissue Int 41 326 31
117. V Kunzmann E Bauer M Wilhelm 1999 Gamma/delta T-cell stimulation by pamidronate N Engl J Med 340 737 8
118. Y Tanaka CT Morita Y Tanaka E Nieves MB Brenner BR Bloom 1995 Natural and synthetic non-peptide antigens recognized by human gamma delta T cells Nature 375 155 8
119. JF Bukowski CT Morita MB Brenner 1999 Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity Immunity 11 57 65
120. V Kunzmann E Bauer J Feurle F Weissinger HP Tony M Wilhelm 2000 Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma Blood 96 384 92
121. T Chen J Berenson R Vescio R Swift A Gilchick S Goodin P LoRusso P Ma C Ravera F Deckert H Schran J Seaman A Skerjanec 2002 Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases J Clin Pharmacol 42 1228 36
122. V Kunzmann J Engert P Reimer F Weissinger T Herrmann M Wilhelm 2003 Crucial role of monocytes in aminobisphosphonate recognition by gamma delta T cells Blood 102 39B
123. K Thompson MJ Rogers 2004 Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro J Bone Miner Res 19 278 88
124. HJ Gober M Kistowska L Angman P Jeno L Mori G De Libero 2003 Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells J Exp Med 197 163 8
125. RE Hewitt A Lissina AE Green ES Slay DA Price AK Sewell 2005 The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins Clin Exp Immunol 139 101 11
126. DH Schweitzer M Oostendorp-van de Ruit G Van der Pluijm CW Lowik SE Papapoulos 1995 Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate J Bone Miner Res 10 956 62
127. A Sauty M Pecherstorfer I Zimmer-Roth P Fioroni L Juillerat M Markert H Ludwig P Leuenberger P Burckhardt D Thiebaud 1996 Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy Bone 18 133 9
128. D Thiebaud A Sauty P Burckhardt P Leuenberger L Sitzler JR Green A Kandra J Zieschang P Ibarra de 1997 An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates Calcif Tissue Int 61 386 92
129. M Kronenberg A Rudensky 2005 Regulation of immunity by self-reactive T cells Nature 435 598 604
130. V Kunzmann M Wilhelm 2005 Anti-lymphoma effect of gammadelta T cells Leuk Lymphoma 46 671 80
131. M Wilhelm V Kunzmann S Eckstein P Reimer F Weissinger T Ruediger HP Tony 2003 Gammadelta T cells for immune therapy of patients with lymphoid malignancies Blood 102 200 6
132. F Dieli N Gebbia F Poccia N Caccamo C Montesano F Fulfaro C Arcara MR Valerio S Meraviglia C Di Sano G Sireci A Salerno 2003 Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo Blood 102 2310 1
133. E Espinosa C Belmant F Pont B Luciani R Poupot F Romagne H Brailly M Bonneville JJ Fournie 2001 Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells J Biol Chem 276 18337 44